Clinical trial
Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin…
NCT00139061 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00139061 |
|---|---|
| Title | Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate |
| Official title | Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hyperlipidemia |
| Intervention type | Drug |
| Interventions | Torcetrapib/Atorvastatin, Fenofibrate |
| Enrollment | 128 |
| Start date | Mar 1, 2005 |
| Completion | May 1, 2006 |
| First posted | Aug 30, 2005 |
| Last update posted | Oct 31, 2007 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: